Searchable abstracts of presentations at key conferences in endocrinology

ea0005s43 | Management of Craniopharyngioma | BES2003

Quality of survival and prognosis for children with craniopharyngioma

Price D

The low incidence of new cases of craniopharyngioma, 1-2 per million per year, and the great variability of morbidity at presentation, have made the evaluation of optimal tumour management extremely difficult. Two patterns of management have evolved over the last 3 decades, namely the performance of 'definitive' radical surgery at onset followed by the use of irradiation to deal with any later recurrence and subtotal tumour resection at onset followed by early irradiation to p...

ea0002p100 | Thyroid | SFE2001

Low as opposed to fully suppressed serum TSH levels in ambulant subjects; frequently a pointer to thyroid autonomy

Chatterjee S , O'Malley B , Price D , Fielding A , Aitken R

In laboratories employing 'front-line' sensitive TSH measurement, it is generally accepted that fully suppressed TSH levels (3rd generation assays) alongside normal free thyroid hormone levels indicate subclinical hyperthyroidism. However, low but not suppressed levels are often labelled as non-thyroidal illness.We investigated 25 successive ambulant individuals, identified over an 18 month period as having low but not fully suppressed TSH levels (3rd ge...

ea0007p136 | Growth and development | BES2004

The value of the TRH test in the assessment of hypothalamic-pituitary disorders in children

Tatnall S , Slim B , Kumar K , Patel L , Hall C , Price D , Clayton P

The TRH test is used in the diagnosis of hypothalamic-pituitary (hp) disorders in children. It is unclear how often the result of this test is helpful. We have examined the results of TRH testing in 143 children investigated primarily for disordered growth. Children with hp axis tumours were excluded.The TSH response to TRH (5microg/kg iv) was defined as abnormal if the peak TSH was <5mU/L (pituitary), or if the peak TSH at 60 mins was higher than at ...

ea0004p12 | Clinical case reports | SFE2002


Das U , Issac H , Kanchi H , Price D , Humphrey G , Hall C

SEVERE HYPERCALCEMIA CAUSED BY A VISIBLE PARATHYROID ADENOMA IN AN ADOLESCENT FEMALEU.Das1, H Iassac1, H Kanchi1, DA Price1, GM Humphrey2 & C M Hall1Departments of 1Endocrinology and 2Surgery, Royal Manchester Children's Hospital, Manchester, Hospital Road, Manchester M27 4HA.A 16-year-old female collapsed following a 24-hour history of severe abdominal pain and vomiting. She was shocked, hypertensive (16...

ea0003p222 | Reproduction | BES2002

Androgen status and female sexual dysfunction in healthy pre-menopausal women

Nyunt A , Stephen G , Fielding A , Wheeler M , Gibbin J , Durgan L , Price D

Androgen deficiency may contribute to sexual dysfunction in hypoadrenalism but its role in normal female physiology is uncertain. The aim of this study was to determine the role of androgens in the aetiology of sexual dysfunction in healthy women. Twenty-nine premenopausal women with loss of libido (subjects) and 13 healthy females (controls) were studied. They were aged 18 to 45 years and in a stable heterosexual relationship. Venous blood was taken at 9 am in the follicular ...

ea0009p55 | Growth and development | BES2005

Constitutional delay of growth and puberty (CDGP)is associated with the GPR54 gene but not with Leptin (L), Leptin Receptor (LR) and Cocaine and Amphetamin Regulated Transcript (CART) genes

Banerjee I , Trueman J , Patel L , Hall C , Price D , Hirschhorn J , Palmert M , Read A , Clayton P

CDGP is a common growth disorder, often dominantly inherited. Genetic association is thus very likely. There are many possible candidates but none are yet linked to CDGP. We assessed the possible contribution of L, LR genes (mutations in each cause very delayed or absent puberty), CART (mediates the effect of L on GnRH pulse generation), and GPR54 (a hypothalamic G-protein coupled receptor, which is mutated in familial hypogonadotrophic hypogonadism) genes.<p class="abstex...

ea0003p164 | Growth and Development | BES2002

Monitoring insulin-like growth factor-I and IGF binding protein-3 in children and adolescents on GH treatment using filter paper blood spots

Das U , Price D , Khosravi J , Wales J , Butler G , Kibirige M , Diamandi A , Jones J , Hall C , Clayton P

In childhood an appropriate response to GH treatment is achieved by titration of growth response against dose administered, with careful observation for side-effects. In order to evaluate the potential use of IGF monitoring in children treated with GH, a cross-sectional study has been carried in 215 children and adolescents (134 with GH deficiency, 54 with Turner syndrome and 29 with non-GHD growth disorders) treated with GH for 0.2 to 13.7 years.IGF-I ...